In preparing amorphous solid dispersions (ASDs) to increase bioavailability, Eudragit L100 has proven a useful excipient, due to its favorable impact on ASD physical stability and dissolution performance. However, when Eudragit L100 is spray-dried, high-aspect-ratio filaments can form, which negatively impact downstream ASD performance and dosage form manufacturability. This paper describes a study of how such filaments form and a particle-design space that identifies key processing parameters that can be used to mitigate the risk of filament formation. To learn more, please read our publication.
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center